Ulcerative Colitis

Because of the body's irregular immune response to IBD, it is widely believed that the condition causes inflammation problems in other parts of the body including joints (arthritis), the eyes and the liver.

IBD patients also exhibit increased risk of colon cancer.

Dr.

Gregersen and his team will conduct the sample genotyping on an automated Illumina BeadStation using the Sentrix HumanHap300 BeadChip that can query over 317,000 tagSNPs on a single microarray device.

The new BeadChip is powered by Illumina's Infinium assay, which enables the intelligent selection and analysis of virtually any SNP in the genome.

The high statistical value of the SNP loci in the HumanHap300 enables researchers to achieve the broadest genomic coverage of any array on the market.

The HumanHap300 delivers industry-leading data quality, with call rates exceeding 99%, and reproducibility and Mendelian accuracy both greater than 99.9%.

"We're delighted that the NIDDK IBD Genetics Consortium has selected Illumina technologies for this important study, said Jay Flatley, Illumina President and CEO.

"We are also very pleased to work once again with Peter Gregersen and to support his vision for making control genotyping data available to the scientific communit...

XIFAXAN C.

difficile-Associated Diarrhea (CDAD) XIFAXAN (rifaximin), dosed 400 mg three times daily, is being investigated in a vancomycin comparator, 300-subject Phase III trial to evaluate the efficacy and safety of XIFAXAN for the treatment of CDAD.

Research by Dr.

Ciaran Kelly, Harvard School of Medicine; Dr.

Dan Gerding, Hines VA Hospital and other investigators provides the theoretical basis for the development of XIFAXAN as a treatment for CDAD.

Poster presentations of recent preclinical work by Drs.

Kelly and Gerding were presented December 16-19, 2005 at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Washington, D.C.

Results of a hamster model study of CDAD, conducted by Dr.

Kelly, demonstrated that rifaximin-treated and vancomycin-treated, CDAD-challenged animals achieved similar survival rates.

Due to the common recurrence of CDAD in the clinical setting, the hamsters were followed after the discontinuation of treatment.

Seventy-five percent of animals treated with vancomycin developed recurrent C.

difficile cecitis (inflammation of the cecum) within 21 day...

XIFAXAN C.

difficile-Associated Diarrhea (CDAD) XIFAXAN (rifaximin), dosed 400 mg three times daily, is being investigated in a vancomycin comparator, 300-subject Phase III trial to evaluate the efficacy and safety of XIFAXAN for the treatment of CDAD.

Research by Dr.

Ciaran Kelly, Harvard School of Medicine; Dr.

Dan Gerding, Hines VA Hospital and other investigators provides the theoretical basis for the development of XIFAXAN as a treatment for CDAD.

Poster presentations of recent preclinical work by Drs.

Kelly and Gerding were presented December 16-19, 2005 at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Washington, D.C.

Results of a hamster model study of CDAD, conducted by Dr.

Kelly, demonstrated that rifaximin-treated and vancomycin-treated, CDAD-challenged animals achieved similar survival rates.

Due to the common recurrence of CDAD in the clinical setting, the hamsters were followed after the discontinuation of treatment.

Seventy-five percent of animals treated with vancomycin developed recurrent C.

difficile cecitis (inflammation of the cecum) within 21 days of...